Close Menu

NEW YORK – Prometheus Biosciences said today that it has entered into a global strategic collaboration with Takeda Pharmaceutical to discover, develop, and commercialize therapies for inflammatory bowel disease.

The firms anticipate combining the Prometheus bioinformatics platform and advanced machine learning techniques with Takeda's expertise in drug development to deliver a new generation of IBD therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.